Drugs / Omega-3 PUFAs
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT07067515 | Jan 2024 → Aug 2025 overdue | hyperpigmentation of the skin | Suez Canal University | Active not recruiting | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT05389046 | Aug 2022 → Dec 2024 | — | Peking University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Omega3(PUFAs) | “Group I was given a daily oral dose of 2 g of Omega-3 PUFAs before and after one weekly intragingival injections of 1–2 g of omega-3.” PMID 42046081 ↗ Apr 20263“Each capsule contains 1 gram of Omega3(PUFAs) as an additional food supplement” NCT07067515 ↗ “1-2 gram /0.1-0.2 ml of Omega-3 (PUFAs) will be injected into the gingiva” NCT07067515 ↗ |
| Known as | Omega-3 poly unsaturated fatty acids | “Effectiveness of Omega-3 Poly Unsaturated Fatty Acids on The Treatment of Gingival Hyperpigmentation” NCT07067515 ↗ |
| Route | Other | “1-2 gram /0.1-0.2 ml of Omega-3 (PUFAs) will be injected into the gingiva” NCT07067515 ↗ |